LEXX News and Press, Lexaria Bioscience Corp. From 01/29/24

Lexaria, a global innovator in drug delivery platforms, has announced its GLP-1 research plans for the 2024 calendar year The company will kick off its chronic dosing animal study in March/April, followed by the human pilot study #2, kicking off at around the same time The third human pilot s...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has released a shareholder letter from CEO Chris Bunka. In the letter, Bunka notes that near the end of 2023, 446 companies on the NASDAQ were trading under $1 and at risk of being delisted compared to almos...

2024-01-22 08:51:37 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lexaria Bioscience (NASDAQ: LEXX ) just reported results for the first quarter of 2024. Lexaria Bioscience reported earnings per share of -13 cents. The company report...

Lexaria, a global specialist in drug delivery platforms, just announced the final results from its recently completed human Pilot Study #1 on the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of GLP-1 drug, semaglutide The results showed improved delivery of sema...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today unveiled a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global ...

(TheNewswire) Extensive work program designed to support commercial discussions. Kelowna, British Columbia – TheNewswire - January 16, 2024 – Lexaria Bioscience Corp. (Nasdaq:LEXX ) (Nasdaq: LEXXW) (the “Company” or “Lexaria...

Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, is committed to providing healthier delivery methods of drugs and other active pharmaceutical ingredients (“APIs”) through its patented drug delivery technology, DehydraTECH(TM). “The com...

NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.” To hear the AudioPressRelease, please vi...

2024-01-10 08:30:36 ET NetworkNewsWire Editorial Coverage New York, NY – January 10, 2024 – On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 dia...

NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN ...